Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

Nature Reviews Drug Discovery

Volumn 8, Issue 10, 2009, Pages 794-805

  Imig, John D ^a   Hammock, Bruce D ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOHEXYL 3 DODECYL UREA; 1 TRIFLUOROMETHOXYPHENYL 3 (1 ACETYLPIPERIDIN 4 YL)UREA; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXYL]BENZOIC ACID; AR 9281; CYTOCHROME P450 2C; EPOXIDE HYDROLASE; EPOXYEICOSANOID; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; ICOSANOID; N CYCLOHEXYL N DODECYL UREA; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITOR INTERACTION; GENETIC VARIABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; VASCULAR DISEASE; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; SIGNAL TRANSDUCTION;

EID: 70349636047     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2875     Document Type: Review

References (148)

1. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
2. Grosser, T., Fries, S. & FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
3. Puri, A., McGoon, M. D. & Kushwaha, S. S. Pulmonary arterial hypertension: Current therapeutic strategies. Nature Clin. Pract. Cardiovasc. Med. 4, 319-329 (2007).
4. Steiropoulos, P., Trakada, G. & Bouros, D. Current pharmacological treatment of pulmonary arterial hypertension. Curr. Clin. Pharmacol. 3, 11-19 (2008).
5. Braden, G. L., O'Shea, M. H., Mulhern, J. G. & Germain, M. J. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol. Dial. Transplant. 19, 1149-1153 (2004).
6. Fries, S. & Grosser, T. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am. Soc. Hematol. Educ. Program 2005, 445-451 (2005).
7. Capra, V. et al. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. Med. Res. Rev. 27, 469-527 (2007).
8. Ribeiro, J. D., Toro, A. A. & Baracat, E. C. Antileukotrienes in the treatment of asthma and allergic rhinitis. J. Pediatr. (Rio J.) 82, S213-S221 (2006).
9. Capdevila, J., Marnett, L. J., Chacos, N., Prough, R. A. & Estabrook, R. W. Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc. Natl Acad. Sci. USA 79, 767-770 (1982).
10. Chacos, N., Falck, J. R., Wixtrom, C. & Capdevila, J. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem. Biophys. Res. Commun. 104, 916-922 (1982).
11. Oliw, E. H., Lawson, J. A., Brash, A. R. & Oates, J. A. Arachidonic acid metabolism in rabbit renal cortex. Formation of two novel dihydroxyeicosatrienoic acids. J. Biol. Chem. 256, 9924-9931 (1981).
12. Ishizuka, T. et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-κB activation and the production of inflammatory cytokines in human endothelial cells. J. Pharmacol. Exp. Ther. 324, 103-110 (2008).
13. Roman, R. J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185 (2002).
14. Sarkis, A., Lopez, B. & Roman, R. J. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr. Opin. Nephrol. Hypertens. 13, 205-214 (2004).
15. Renic, M. et al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 29, 629-639 (2009).
16. Miyata, N. et al. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N′-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J. Pharmacol. Exp. Ther. 314 77-85 (2005).
17. Campbell, W. B., Gebremedhin, D., Pratt, P. F. & Harder, D. R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78, 415-423 (1996).
18. Fleming, I. DiscrEET regulators of homeostasis: Epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol. Sci. 28, 448-452 (2007).
19. Gross, G. J. et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294 H2838-H2844 (2008).
20. Imig, J. D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289 F496-F503 (2005).
21. Spector, A. A., Fang, X., Snyder, G. D. & Weintraub, N. L. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog. Lipid Res. 43, 55-90 (2004).
22. Jacobson, H. R. et al. in Prostaglandins and Membrane Ion Transport (eds Braquet, P. Garay, R. P., Frohlich, J. C. & Nicosia, S) 311-318 (Raven Press, New York, 1985).
23. Proctor, K. G., Falck, J. R. & Capdevila, J. Intestinal vasodilation by epoxyeicosatrienoic acids: Arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. Circ. Res. 60, 50-59 (1987).
24. Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 50, S52-S56 (2009).
25. Yang, W. et al. Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding. J. Pharmacol. Exp. Ther. 321, 1023-1031 (2007).
26. Widstrom, R. L., Norris, A. W., Van Der Veer, J. & Spector, A. A. Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry 42, 11762-11767 (2003).
27. Liu, Y. et al. The antiinflammatory effect of laminar flow: The role of PPAR, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl Acad. Sci. USA 102, 16747-16752 (2005).
28. Michaelis, U. R. & Fleming, I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol. Ther. 111, 584-595 (2006).
29. Spector, A. A. & Norris, A. W. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292, C996-C1012 (2007).
30. Fleming, I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 82, 60-67 (2007).
31. Breyer, R. M., Bagdassarian, C. K., Myers, S. A. & Breyer, M. D. Prostanoid receptors: Subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41, 661-690 (2001).
32. Hao, C. M. & Breyer, M. D. Physiological regulation of prostaglandins in the kidney. Annu. Rev. Physiol. 70, 357-377 (2008).
33. Gebremedhin, D. et al. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am. J. Physiol. 263, H519-H525 (1992).
34. Imig, J. D., Navar, L. G., Roman, R. J., Reddy, K. K. & Falck, J. R. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 7, 2364-2370 (1996).
35. Keseru, B. et al. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. Faseb J. 22 4306-4315 (2008).
36. Pokreisz, P. et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47, 762-770 (2006).
37. Ca channels. Circulation 107, 769-776 (2003).
38. Fisslthaler, B. et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401, 493-497 (1999).
39. Ca channels in coronary arterial smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 282 H1229-H1236 (2002).
40. Imig, J. D., Inscho, E. W., Deichmann, P. C., Reddy, K. M. & Falck, J. R. Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 33, 408-413 (1999).
41. Li, P. L., Chen, C. L., Bortell, R. & Campbell, W. B. 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ. Res. 85, 349-356 (1999).
42. Node, K. et al. Activation of Gβs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276, 15983-15989 (2001).
43. Ca channels: Implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290, H491-H499 (2006).
44. Medhora, M. et al. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat. 82, 19-29 (2007).
45. Medhora, M. et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 284, H215-H224 (2003).
46. Potente, M., Fisslthaler, B., Busse, R. & Fleming, I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem. 278, 29619-29625 (2003).
47. Potente, M., Michaelis, U. R., Fisslthaler, B., Busse, R. & Fleming, I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J. Biol. Chem. 277, 15671-15676 (2002).
48. Pozzi, A. et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem. 280, 27138-27146 (2005).
49. Yan, G., Chen, S., You, B. & Sun, J. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc. Res. 78, 308-314 (2008).
50. Sun, J. et al. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90, 1020-1027 (2002).
51. Davis, B. B. et al. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J. Pharmacol. Exp. Ther. 316, 815-821 (2006).
52. Davis, B. B. et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl Acad. Sci. USA 99, 2222-2227 (2002).
53. Foley, R. N. & Collins, A. J. End-stage renal disease in the United States: An update from the United States Renal Data System. J. Am. Soc. Nephrol. 18, 2644-2648 (2007).
54. Zoccali, C., Mallamaci, F. & Tripepi, G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. Suppl. 85, S105-S110 (2003).
55. Elmarakby, A. A. et al. Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. Hypertension 50, 1069-1076 (2007).
56. Elmarakby, A. A., Quigley, J. E., Pollock, D. M. & Imig, J. D. Tumor necrosis factor a blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47, 557-562 (2006).
57. Node, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279 (1999).
58. Falck, J. R. et al. 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-α-induced VCAM-1 expression. Bioorg Med. Chem. Lett. 13, 4011-4014 (2003).
59. Fitzpatrick, F. A. et al. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J. Biol. Chem. 261, 15334-15338 (1986).
60. Pratt, P. F., Rosolowsky, M. & Campbell, W. B. Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. Life Sci. 70, 2521-2533 (2002).
61. Heizer, M. L., McKinney, J. S. & Ellis, E. F. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 22, 1389-1393 (1991).
62. Kozak, W., Kluger, M. J., Kozak, A., Wachulec, M. & Dokladny, K. Role of cytochrome P-450 in endogenous antipyresis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R455-R460 (2000).
63. Nakashima, T., Yoshida, Y., Miyata, S. & Kiyohara, T. Hypothalamic 11,12-epoxyeicosatrienoic acid attenuates fever induced by central interleukin-1β in the rat. Neurosci. Lett. 310, 141-144 (2001).
64. Schmelzer, K. R. et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl Acad. Sci. USA 103, 13646-13651 (2006).
65. Imig, J. D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc. Drug Rev. 24, 169-188 (2006).
66. Inceoglu, B. et al. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 79, 2311-2319 (2006).
67. Zhao, X. et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15, 1244-1253 (2004).
68. Smith, K. R. et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl Acad. Sci. USA 102, 2186-2191 (2005).
69. Fornage, M. et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335-339 (2004).
70. Fornage, M. et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum. Mol. Genet. 14, 2829-2837 (2005).
71. Koerner, I. P. et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J. Neurosci. 27, 4642-4649 (2007).
72. Lee, C. R. et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15, 1640-1649 (2006).
73. Srivastava, P. K., Sharma, V. K., Kalonia, D. S. & Grant, D. F. Polymorphisms in human soluble epoxide hydrolase: Effects on enzyme activity, enzyme stability, and quaternary structure. Arch. Biochem. Biophys. 427, 164-169 (2004).
74. Wei, Q. et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking. Atherosclerosis 190, 26-34 (2007).
75. Sato, K. et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: Intrafamilial association study in an eight-generation hyperlipidemic kindred. J. Hum. Genet. 49, 29-34 (2004).
76. Dreisbach, A. W. et al. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens. 18, 1276-1281 (2005).
77. Spiecker, M. et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110, 2132-2136 (2004).
78. Yu, Z. et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992-998 (2000).
79. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. & Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694 (2002).
80. Imig, J. D. et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975-981 (2005).
81. Morisseau, C. & Hammock, B. D. Gerry Brooks and epoxide hydrolases: Four decades to a pharmaceutical. Pest Manag. Sci. 64, 594-609 (2008).
82. Newman, J. W., Morisseau, C. & Hammock, B. D. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog. Lipid Res. 44, 1-51 (2005).
83. Oesch, F., Schladt, L., Hartmann, R., Timms, C. & Worner, W. Rat cytosolic epoxide hydrolase. Adv. Exp. Med. Biol. 197, 195-201 (1986).
84. EnayetAllah, A. E. et al. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J. Biol. Chem. 283, 36592-36598 (2008).
85. Morisseau, C. & Hammock, B. D. Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45, 311-333 (2005).
86. Newman, J. W., Morisseau, C., Harris, T. R. & Hammock, B. D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl Acad. Sci. USA 100, 1558-1563 (2003).
87. Enayetallah, A. E., French, R. A., Thibodeau, M. S. & Grant, D. F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52, 447-454 (2004).
88. Yu, Z. et al. Vascular localization of soluble epoxide hydrolase in the human kidney. Am. J. Physiol. Renal Physiol. 286, F720-F726 (2004).
89. Harris, T. R. et al. Identification of two epoxide hydrolases in Caenorhabditis elegans that metabolize mammalian lipid signaling molecules. Arch. Biochem. Biophys. 472, 139-149 (2008).
90. Tran, K. L. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry 44, 12179-12187 (2005).
91. Harris, T. R., Aronov, P. A. & Hammock, B. D. Soluble epoxide hydrolase homologs in Strongylocentrotus purpuratus suggest a gene duplication event and subsequent divergence. DNA Cell Biol. 27 467-477 (2008).
92. Mullin, C. A. & Hammock, B. D. Chalcone oxides - potent selective inhibitors of cytosolic epoxide hydrolase. Arch. Biochem. Biophys. 216, 423-439 (1982).
93. Morisseau, C. et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl Acad. Sci. USA 96, 8849-8854 (1999).
94. Kim, I. H. et al. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J. Med. Chem. 48, 3621-3629 (2005).
95. Morisseau, C. et al. Development of metabolically stable inhibitors of mammalian microsomal epoxide hydrolase. Chem. Res. Toxicol. 21, 951-957 (2008).
96. Xie, Y. et al. Discovery of potent non-urea inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 19, 2354-2359 (2009).
97. Liu, J.-Y. et al. Sorafenib has soluble epoxide hydrolase inhibitory activity which contributes to its effect profile in vivo. Mol. Cancer Ther. 8, 2193-2203 (2009).
98. Ghosh, S. et al. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 102, 453-458 (2008).
99. Morisseau, C. et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 63 1599-1608 (2002).
100. Hwang, S. H., Tsai, H. J., Liu, J. Y., Morisseau, C. & Hammock, B. D. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 50, 3825-3840 (2007).
101. Ai, D. et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl Acad. Sci. USA 106, 564-569 (2009).
102. Jung, O. et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765 (2005).
103. Koerner, I. P. et al. Soluble epoxide hydrolase: Regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front. Biosci. 13, 2833-2841 (2008).
104. Seubert, J. M. et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99, 442-450 (2006).
105. Ulu, A. et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model. J. Cardiovasc. Pharmacol. 52, 314-323 (2008).
106. Marino, J. P. Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr. Top. Med. Chem. 9, 452-463 (2009).
107. Olearczyk, J. J. et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond.) 116, 61-70 (2009).
108. Motoki, A. et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 295, H2128-H2134 (2008).
109. Fife, K. L. et al. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J. Pharmacol. Exp. Ther. 327, 707-715 (2008).
110. Katragadda, D. et al. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J. Mol. Cell Cardiol. 46, 867-875 (2009).
111. Loch, D., Hoey, A., Morisseau, C., Hammock, B. O. & Brown, L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 47, 87-98 (2007).
112. Fleming, I. Vascular cytochrome p450 enzymes: Physiology and pathophysiology. Trends Cardiovasc. Med. 18, 20-25 (2008).
113. Fornage, M. et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40, 485-490 (2002).
114. Dorrance, A. M. et al. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 46, 842-848 (2005).
115. Simpkins, A. N. et al. Soluble epoxide hydrolase inhibition is protective against cerebral ischemia via vascular and neural protection. Am. J. Pathol. 174, 2086-2095 (2009).
116. Corenblum, M. J. et al. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 51, 567-573 (2008).
117. Sinal, C. J. et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275, 40504-40510 (2000).
118. Luria, A. et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282, 2891-2898 (2007).
119. Manhiani, M. et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 24 Jun 2009 (doi:10.1152/ ajprenal.00098.2009).
120. Parrish, A. R. et al. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 25 217-225 (2008).
121. Xu, D. et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl Acad. Sci. USA 103, 18733-18738 (2006).
122. Li, J. et al. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front. Biosci. 13, 3480-3487 (2008).
123. Hutchens, M. P. et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 76, 89-94 (2008).
124. Zhang, W. et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39 2073-2078 (2008).
125. Zhang, W. et al. Soluble epoxide hydrolase: A novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27, 1931-1940 (2007).
126. Ai, D. et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 104, 9018-9023 (2007).
127. Schmelzer, K. R. et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl Acad. Sci. USA 102 9772-9777 (2005).
128. Fang, X. et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J. Pharmacol. Exp. Ther. 314, 260-270 (2005).
129. Buckingham, R. E. & Hanna, A. Thiazolidinedione insulin sensitizers and the heart: A tale of two organs? Diabetes Obes. Metab. 10, 312-328 (2008).
130. Liu, M. & Alkayed, N. J. Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1 α-linked induction of P450 2C11 epoxygenase in astrocytes. J. Cereb. Blood Flow Metab. 25, 939-948 (2005).
131. Terashvili, M. et al. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of β-endorphin and metenkephalin in the rat ventrolateral periaqueductal gray. J. Pharmacol. Exp. Ther. 326, 614-622 (2008).
132. Iceoglu, B. et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc. Natl Acad. Sci. USA 105, 18901-18906 (2008).
133. Yang, S., Wei, S., Pozzi, A. & Capdevila, J. H. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch. Biochem. Biophys. 21 May 2009 (doi:10.1016/j.abb.2009.05.006).
134. Cheranov, S. Y. et al. An essential role for SRC-activated STAT-3 in 14, 15-EET-induced VEGF expression and angiogenesis. Blood 111, 5581-5591 (2008).
135. Revermann, M. et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J. Hypertens. 27, 322-331 (2009).
136. Alvarez, D. F., Gjerde, E. A. & Townsley, M. I. Role of EETs in regulation of endothelial permeability in rat lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L445-L451 (2004).
137. Jian, M. Y., King, J. A., Al-Mehdi, A. B., Liedtke, W. & Townsley, M. I. High vascular pressure-induced lung injury requires P450 epoxygenase-dependent activation of TRPV4. Am. J. Respir. Cell. Mol. Biol. 38, 386-392 (2008).
138. Morin, C., Sirois, M., Echave, V., Gomes, M. M. & Rousseau, E. EET displays anti-inflammatory effects in TNF-á stimulated human bronchi: putative role of CPI-17. Am. J. Respir. Cell. Mol. Biol. 38, 192-201 (2008).
139. Krotz, F. et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler. Thromb. Vasc. Biol. 24, 595-600 (2004).
140. Jiang, J. G. et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65, 4707-4715 (2005).
141. Chen, C. et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J. Pharmacol. Exp. Ther. 329, 908-918 (2009).
142. + channels and p42/p44 MAPK pathway. Circ. Res. 95, 506-514 (2004).
143. Yang, Q., Zhang, R. Z., Yim, A. P. & He, G. W. Effect of 11, 12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann. Thorac. Surg. 76, 1623-1630 (2003).
144. Falck, J. R. et al. Comparison of vasodilatory properties of 14, 15-EET analogs: Structural requirements for dilation. Am. J. Physiol. Heart Circ. Physiol. 284, H337-H349 (2003).
145. Gauthier, K. M., Falck, J. R., Reddy, L. M. & Campbell, W. B. 14,15-EET analogs: Characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol. Res. 49, 515-524 (2004).
146. + channels. Microcirculation 15 137-150 (2008).
147. Imig, J. D. & Falck, J. R. Compositions and methods for the treatment of renal and cardiovascular disease. US Patent 2008146663 (2008).
148. Olearczyk, J. J. et al. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J. Pharmacol. Exp. Ther. 318, 1307-1314 (2006).